Group 1 - The core viewpoint of the news highlights the significant stock performance of 加科思-B (JACOB) with a year-to-date increase of 513.39%, outperforming the Hang Seng Index by 27.24% [1] - As of July 30, the stock price of 加科思-B closed at 8.82 HKD per share, with a trading volume of 26.44 million shares and a turnover of 233 million HKD, reflecting a volatility of 25.29% [1] - Financial data shows that for the year ending December 31, 2024, 加科思-B achieved total revenue of 156 million HKD, representing a year-on-year growth of 145.13%, while the net profit attributable to shareholders was -156 million HKD, with a growth of 56.64% [1] Group 2 - 加科思药业集团有限公司 is primarily engaged in the research and development of clinical-stage new drugs, focusing on innovative cancer therapies [2] - The company is responsible for the discovery and development of its own drug candidates, including clinical-stage allosteric SHP2 inhibitors JAB-3068 and JAB-3312 [2] - The company mainly operates in the domestic market of China [2] Group 3 - As of July 28, 2025, the company repurchased 47,400 shares at a price range of 7.47-7.49 HKD per share, totaling a repurchase amount of 354,500 HKD [3]
加科思-B（01167.HK）7月30日收盘上涨13.22%，成交2.33亿港元